source
- FDA staff flag no major concerns for Grail's multi-cancer test ahead of advisory committeeFDA staff have completed a review of Grail's multi-cancer early detection test and reported no major concerns. The assessment comes as the test approaches a scheduled advisory committee meeting, w…
- Novo outlines diversification strategy with new pipeline assets and bolt-on dealsNovo Pharmaceuticals' chief executive Maziar Mike Doustdar used the company's recent capital-markets day in London to lay out a diversification plan. He said the rebranded firm will focus on expand…